CCN3 and myeloid sarcoma: Ultimately, the robust expression of CCN3 in the periphery and CNS of individuals with MS shows that there is not an obvious CCN3 deficiency in MS that should be directly targeted therapeutically, but its altered profile of expression potentially points to additional cellular players, functions and regulatory mechanisms.